Role of Immunoscore® in Stage II-III Colorectal Cancer

Status Recruiting

Clinical Trial Summary

The proposed study is a bidirectional analytical study, composed of a retrospective and a prospective cohorts. Patients with stage II - III colorectal cancer undergoing oncological surgery will be analyzed. The study will include a convenience sample of 100 individuals. Fifty cases will be included retrospectively and fifty prospectively. The study aims to evaluate the benefit of using the Immunoscore test as a predictor of recurrence in patients with operated stage II-III colon tumors. It will also be evaluated the impact on oncologic decision and costs.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05422547
Study type	Observational
Source	D'Or Institute for Research and Education
Contact	Camila M Moniz, PhD
Phone	55 11 2109-8855
Email	camila.venchiarutti@idor.org
Status	Recruiting
Phase
Start date	April 1, 2022
Completion date	December 30, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04003181` - The Pathogenesis of Chronic Diarrhoea After Treatment for Cancer in Cecum and the Ascending Colon	N/A
Active, not recruiting	`NCT04057274` - Acute Effect of modeRate-intensity aerOBIc Exercise on Colon Cancer Cell Growth	N/A
Completed	`NCT02127359` - Whole-Exome Sequencing (WES) of Cancer Patients
Completed	`NCT00096278` - Fluorouracil, Leucovorin, and Oxaliplatin With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II or Stage III Colon Cancer	Phase 3
Active, not recruiting	`NCT02912559` - Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair	Phase 3
Completed	`NCT02569723` - Oxaliplatin Microdosing Assay in Predicting Exposure and Sensitivity to Oxaliplatin-Based Chemotherapy	N/A
Recruiting	`NCT05746195` - Optimization of Adaptive Text Messages for Cancer Survivors (OATS II)	N/A
Active, not recruiting	`NCT03365882` - S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery	Phase 2
Completed	`NCT02393755` - Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal Cancer	Phase 1/Phase 2
Recruiting	`NCT05710406` - Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer	Phase 2/Phase 3
Recruiting	`NCT06017141` - Inhalational or Intravenous Anesthesia During Surgery for Patients With Colon Cancer, VIVA Study	Phase 2
Active, not recruiting	`NCT03436563` - M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instability	Phase 1/Phase 2
Recruiting	`NCT05482516` - Evaluating Novel Therapies in ctDNA Positive GI Cancers	Phase 3
Completed	`NCT02368886` - Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer	Phase 2
Active, not recruiting	`NCT02863107` - Young-Onset Colorectal Cancer
Active, not recruiting	`NCT04963283` - Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer	Phase 2
Completed	`NCT05872334` - The Safety and Feasibility of MONOFIX on Fascial Closure of Mid-line Wound After Minimally Invasive Colorectal Cancer Surgery	N/A
Completed	`NCT03949777` - Validation of Aer-O-Scope Colonoscope System Cecal Intubation	N/A
Completed	`NCT06216405` - Performance of Artificial Intelligence in Colonoscopy for Right Colon Polyp Detection	N/A
Recruiting	`NCT05186116` - LDLT in Non Resectable Colo-rectal Cancer Liver Metastasis	N/A